Tickets now on sale for 2023 Manufacturing Chemist Live

Published: 1-Feb-2023
Manufacturing Ingredients Packaging Sustainability Regulatory Drug Delivery Research & Development

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023

Get your discounted ticket today!

Attended by over 350 representatives from companies such as GSK, AstraZeneca, Pfizer and many more, the two-day co-located event with Cleanroom Technology Conference, is the place to be for pharmaceutical professionals, as well as using cleanrooms to showcase, network and do business.

Super early bird tickets are now on sale and offer more than 35% discount on full price conference tickets

Cutting-edge content

The pharmaceutical manufacturing world is in a state of flux. Mega-trends such as automation, digitalisation, modularisation and serialisation are affecting the way companies work and the quality standards they have to meet. But how do they stay current? Are they Pharma 4.0 compatible? Is their plant ready for inspection? Is their facility future-proof and fit for purpose?

The venue

Based at the National Conference Centre in Birmingham, it's at the hub of the country’s motorway system and rail network, with Birmingham International railway station just five-minutes taxi ride away.

For more information, visit the website here or contact Amandine Mareschi on amandine@hpcimedia.com.

  • Companies:
  • GlaxoSmithKline
  • Pfizer
  • AstraZeneca
See more

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

Read more
The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC

Trending Articles

  1. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  2. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  3. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Manufacturing

GSK bolsters its US drug manufacturing capabilities with $800m investment

The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Subscribe now